ACE Inhibitors Market is expected to reach USD 6,742.32 Million by 2030 at 3.40% CAGR during the forecast period 2022-2030.

The growth of the global ACE inhibitors market is determined by numerous factors such as rising adoption of ACE inhibitors for the treatment of cardiovascular complications and diabetic neuropathy, rising cases of cardiovascular disorders such as hypertension, and surge in demand for less expensive drugs. For instance, according to the data published by the World Health Organization (WHO) in 2017, the global prevalence rate of raised blood pressure in adults aged more than 18 was estimated to be 22.1% in 2017. However, ace inhibitors side effects associated with the treatment and high costs of treatment are likely to hamper the growth of the global ACE inhibitors market during the forecast period. 

Regional Analysis

The ACE inhibitors market Research has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the growing prevalence of hypertension and cardiovascular disorders.

The European ACE inhibitors market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The ACE inhibitors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The presence of a huge population base, increasing awareness about cardiovascular disorders, and rising disposable income are the key factors responsible for the fastest growth of the market in Asia-Pacific. The ACE inhibitors market in the Middle East & Africa has been divided into the Middle East and Africa.


The Global ACE Inhibitors Market has been segmented based on Product, Application, Dosage Form, and Distribution Channel.

The market, based on product, has been divided into lisinopril, ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others. The lisinopril is likely to hold the maximum market share in the global ACE inhibitors market owing to the growing adoption of lisinopril in the management of cardiovascular complications and diabetic neuropathy.

The global ACE inhibitors market based on the application has been segregated into heart failure, hypertension, diabetes, heart attack, chronic kidney disease, and others. The hypertension segment is expected to hold a larger share of the market share owing to the rising cases of hypertension and the adoption of ACE inhibitors.

The ace inhibitors dosage form segment of the market is divided into oral tablets and oral solution. Capoten, Vasotec, Prinivil, Zestril, Lotensin, Monopril, and Altace are some well-known and widely used oral tablets.

Based on distribution channel, the global ACE inhibitors market has been segmented into retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others. Retail pharmacy holds maximum market share during the forecast period.

Key Players

Some of the Key Players in the Global ACE Inhibitors Market are Bristol-Myers Squibb Company (US), Par Pharmaceutical Companies, Inc. (US), UCB, Inc. (Belgium), Pfizer, Inc.(US), AbbVie Inc.(US), AstraZeneca (UK), Bausch Health Companies Inc.(Canada), Novartis AG (Switzerland), Merck & Co., Inc.(US), Teva Pharmaceutical Industries Ltd.(Israel), Silvergate Pharmaceuticals, Inc. (US), and others.

Access Report Details @

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071